

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549**

**FORM 8-K**

**CURRENT REPORT PURSUANT  
TO SECTION 13 OR 15(D) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): **May 16, 2016**

**BIOTRICITY INC.**

(Exact Name of Registrant as Specified in Its Charter)

Nevada	333-201719	47-2548273
(State or Other Jurisdiction of Incorporation or Organization)	(Commission File Number)	(IRS Employer Identification No.)
75 International Blvd., Suite 300 Toronto, ON		M9W 6L9
(Address of Principal Executive Offices)		(Zip Code)

Registrant's Telephone Number, Including Area Code: (416) 214-3678

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 4.02      Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review**

On May 16, 2016, a Form 10-Q for the fiscal quarter ended March 31, 2016 (the “Original Filing”) of Biotricity, Inc. (the “Registrant”), was filed with the Securities and Exchange Commission (the “SEC”). The Original Filing was not yet finalized or approved for filing by the Registrant but was nevertheless inadvertently filed with the SEC due to an error of the Edgar agent used by the Registrant. Accordingly, the Original Filing should not be relied upon.

The Registrant intends to file a restated Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2016 as soon as practicable.

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: May 17, 2016

BIOTRICITY INC.

By: /s/ Waqaas Al-Siddiq  
Waqaas Al-Siddiq  
Chief Executive Officer